SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Similar documents
SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

NEW ZEALAND DATA SHEET

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

SUMMARY OF PRODUCT CHARACTERISTICS

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients:

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).

3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1. NAME OF THE MEDICINAL PRODUCT. Lamisil 1% cutaneous solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

DOSAGE FORMS AND STRENGTHS White toothpaste containing 1.1% sodium fluoride (3)

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

Used for removing granulation tissue, warts (including verrucas), for cautery and as a caustic

Body weight more than 30kg : 10ml (10mg) of the syrup once daily.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Package Insert. Constipeg

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Light Liquid Paraffin and White Soft Paraffin Cream

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

Summary of Product Characteristics Updated 01-May-2015 Meda Pharmaceuticals

VALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

Summary of Product Characteristics

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution.

NEW ZEALAND DATA SHEET

1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PDF rendering: Titel , Version 1.1, Namn Azelastine OmniVision 0.5 mg per ml eye drops, solution SmPC

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Excipients with known effect: Each gramme of gel contains 1 mg methyl parahydroxybenzoate (E-218) and 0.5 mg propyl parahydroxybenzoate (E-216).

For a full list of excipients, see section 6.1. A sterile, clear, bright, colourless, aqueous solution.

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF THE PRODUCT CHARACTERISTICS

Fixed combination of Valeriana officinalis L., radix (valerian root) and Humulus lupulus L., flos (hop strobile).

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Instil one or two drops in the conjunctival sac(s) every three to four hours as needed.

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Summary of Product Characteristics

Summary of product characteristics (SmPC)

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

CHOLESTAGEL 625 mg Genzyme

ADT Booster Data Sheet

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. One chewable tablet contains 1250 mg calcium carbonate (equivalent to 500 mg calcium).

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.

Indications: For the treatment and control of fascioliasis in cattle and sheep.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

Summary of Product Characteristics

Article 30 Referral for Calcitugg (and associated names) Chewable tablets (Calcium carbonate)

Produktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes.

Transcription:

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT DURAPHAT 2800 ppm FLUORIDE TOOTHPASTE 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium Fluoride 0.619 % w/w (2800 ppm F) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Toothpaste Smooth White Paste For dental use 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For the prevention and treatment of dental caries (coronal and root) in adults and children over 10 years.

4.2 Posology and method of administration Posology Children under 10 years old: not recommended Adults and children over 10 years old: Use daily instead of the normal toothpaste. The usual dosage is to apply a 1 cm line of paste across the head of a toothbrush and brush the teeth thoroughly for one minute morning and evening. Spit out after use; for best results do not drink or rinse for 30 minutes. Elderly: use as for adults. Method of administration For dental use 4.3 Contraindications Hypersensitivity to the active substance(s) or to any of the excipients Individuals with known sensitivities should consult their dentist before using Not to be used in children under 10 years old 4.4. Special warnings and precautions for use Not to be swallowed. 4.5. Interactions with other medicinal products and other forms of interaction None known.

4.6 Fertility, pregnancy and lactation Epidemiological studies in humans indicate that fluoride has no adverse effects in pregnancy or on the health of the foetus or newborn child. No effects during pregnancy are anticipated, since systemic exposure to Sodium Fluoride is negligible. Duraphat 2800 Toothpaste can be used during pregnancy. No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Sodium Fluoride is negligible. Duraphat 2800 Toothpaste can be used during breast-feeding. 4.7. Effects on ability to drive and use machines Not applicable. 4.8 Undesirable effects When used as recommended there are no side effects. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. 4.9 Overdose Symptoms: In very high doses, fluoride can have an acute toxic effect. Doses of several milligrams of fluoride per kg of body weight may cause nausea, vomiting, and diarrhoea. Tetany and convulsion can occur, as well as cardiovascular disorders. Increased risk of bone fracture and skeletal fluorosis (stiffness of joints and skeletal deformities) will only be observed in cases of very high chronic intake of fluoride. Management: Treatment and management should be symptomatic. In case of mild gastrointestinal overdose symptoms a small glass of milk to drink should be given to bind fluoride ion. It should be noted that gut decontamination is contraindicated. Charcoal is of no benefit. 5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: caries prophylactic agents ATC code: A01AA01 This product is a toothpaste in which the active ingredient is Sodium Fluoride present at a level of 0.619% which corresponds to 280 mg fluoride per 100 g paste. Sodium fluoride applied topically after tooth eruption reduces caries by inhibiting demineralisation and promoting remineralisation of the tooth surface. It is effective on both enamel and exposed dentine. 5.2. Pharmacokinetic Properties This product is not intended to be swallowed and therefore only minimal systemic exposure is expected. 5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Glycerol (E 422) Purified Water Sorbitol, liquid (non-crystallizing) (E 420) Silicas Polyethylene glycol 600 Sodium lauryl sulphate Sodium carboxymethylcellulose (E 467) Mint Flavour Titanium dioxide (E 171) Sodium saccharin (E954) 6.2. Incompatibilities Not applicable.

6.3. Shelf life 3 years 6.4. Special precautions for storage Do not store above 25 o C. 6.5 Nature and contents of container 75 ml polyethylene/aluminium/polyethylene laminated tube with a polypropylene screw closure. Pack sizes: 1 x 75ml tube or 2 x 75ml tubes. 6.6 Special precautions for disposal and other handling Not applicable 7. MARKETING AUTHORISATION HOLDER Colgate-Palmolive (U.K.) Ltd Guildford Business Park Middleton Road Guildford Surrey GU2 8JZ United Kingdom 8. MARKETING AUTHORISATION NUMBER PL 00049/0039 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

4 December 2000 10 DATE OF REVISION OF THE TEXT 20/01/2015